HIV and the Seroprevalence of SARS-CoV-2
Abstract
Importance
Healthy HIV-positive insurance applicants have a similar risk of infection and produce a similar antibody response as HIV-negative applicants infected with COVID-19.
Objective
Study the seroprevalence and immune response to COVID-19 in healthy HIV-positive life insurance applicants.
Design
From January 2020 to March 2021, we examined the seroprevalence of COVID-19 in all HIV-positive applicants. Antibody level in 340 age and sex matched COVID-19 positive applicants, 170 HIV-positive and 170 HIV negative, are compared. The data was de-identified of all personal information and separated by month, age and sex.
Participants
Self-reported healthy HIV positive life insurance applicants were tested for antibodies to COVID-19.
Related articles
Related articles are currently not available for this article.